NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court; further details about the cases can be found at the links
provided.
Ormat Technologies, Inc. (NYSE:ORA)
Class Period: August 8, 2017 - May 15, 2018
Lead Plaintiff Deadline: August 8, 2018
During the class period, PG&E allegedly made materially false and/or misleading statements and/or failed to
disclose that: PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety
requirements and regulations promulgated under state law; consequently, PG&E was in violation of state law regulation;
PG&E’s electricity networks would cause numerous wildfires in California; and as a result of the foregoing, Defendants’
statements about the Company’s business and operations were materially false and misleading at all relevant times.
To learn more go to: http://www.zlk.com/pslra-d/ormat-technologies-inc?wire=3.
Newell Brands Inc. (NYSE:NWL)
Class Period: February 6, 2017 - January 24, 2018
Lead Plaintiff Deadline: August 20, 2018
According to the complaint, the Company’s retail channel was loaded with extremely high levels of unsold Newell
product; contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to
Company-specific rather than macroeconomic reasons; as a result of the unusually high levels of unsold inventory in the retail
channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and undisclosed
managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a
material adverse effect on the Company’s operating performance.
To learn more go to: http://www.zlk.com/pslra-d/newell-brands-inc?wire=3.
Flex Pharma, Inc. (NASDAQ:FLKS)
Class Period: November 6, 2017 - June 12, 2018
Lead Plaintiff Deadline: August 20, 2018
During the class period, Flex Pharma overstated the viability and approval prospects for its product candidate
FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and as a result, Flex Pharma's public
statements were materially false and misleading at all relevant times. On June 13, 2018, Flex announced that it planned to halt its
FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its
organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic
alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or
75.12%, to close at $1.04 on June 13, 2018.
To learn more go to: http://www.zlk.com/pslra-d/flex-pharma-inc?wire=3.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to
share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered
hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
